FDA Nominee’s Senate Hearing Puts US Drug Regulation and Vaccine Policy on Watch

Washington, 25 September 2026 – Heidi Overton, the physician nominated to lead the US Food and Drug Administration, faced pointed questioning at a Senate confirmation hearing over vaccines and the agency’s independence. Her nomination has not been confirmed. For pharmaceutical and biotechnology investors, the hearing matters because leadership at the regulator influences how consistently companies can plan clinical programmes, submissions and product launches.

Overton, a White House adviser, said the combined measles, mumps and rubella vaccine is currently licensed and approved, and described it as safe and effective. She also said vaccines presently on the US market are considered safe and effective by the agency. Those statements came after senators asked about administration remarks on vaccination and the current measles outbreak.